Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02034578 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target

NCT02034578: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.

NCT02034578 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02034578, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target

Study Summary

The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy subjects

Primary Outcome

Samples of plasma from participants were obtained at the following times: 0 hour (h) and post dose at 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h. Apixaban was assayed using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method during the period of known analyte stability. Maximum observed plasma concentration (Cmax) was measured in nanograms per milliliter (ng/mL).

Interventions

  • DRUG Apixaban

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2011-07
Est. Completion 2011-08
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT02034578 record still lists

NCT02034578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).

The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.

NCT02034578 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02034578 about?

NCT02034578 is a clinical study titled "Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects". The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy subjects

What is the current status of trial NCT02034578?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2011-07. Estimated completion is 2011-08.

What interventions are being tested in trial NCT02034578?

The interventions under investigation include: Apixaban (DRUG).

Who is sponsoring clinical trial NCT02034578?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02034578's enrollment target sits among peer trials

75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02034578, the US trial registry maintained by the National Library of Medicine. NCT02034578 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.